按行业排序
按基金排序
10/25/21

Bausch + Lomb和Clearside Biomedical宣布FDA批准XIPERE™(曲安奈德注射悬液)用于治疗葡萄膜炎相关黄斑水肿

阅读更多
10/19/21

Castle Biosciences收购cernostic

阅读更多
8/22/21

Solar Power Booms in Georgia, Where It Isn’t Mandated

阅读更多
7/19/21

MINDERA™ ANNOUNCES PUBLICATION OF AN ECONOMIC EVALUATION OF PRECISION MEDICINE TESTING FOR THE TREATMENT OF PSORIASIS

阅读更多
6/17/21

PhaseBio Announces European Licensing Agreement with Alfasigma S.p.A用于Bentracimab的商业化

阅读更多
6/15/21

Clearside Biomedical公布了CLS-AX(阿西替尼注射悬液)治疗湿性AMD OASIS 1/2a期临床试验的1组阳性安全性结果

阅读更多
5/12/21

ALSS Secures $7M Series B Funding To Commercialize Novel Vaccine Delivery System For Poultry Industry

阅读更多
5/11/21

Mindera A-2融资1200万美元

阅读更多
4/30/21

BILLION-DOLLAR RANCH HANDS: How Silicon Ranch became a homegrown powerhouse

阅读更多
4/27/21

Castle Biosciences Signs Definitive Agreement to Acquire Myriad myPath® Laboratory

阅读更多
3/2/21

G1 Therapeutics and Boehringer Ingelheim Announce Commercial Availability of COSELA™ (trilaciclib), fda批准的唯一一种减少化疗诱导骨髓抑制发生率的多谱系骨髓保护疗法

阅读更多
2/12/21

FDA批准G1 Therapeutics的COSELA™(trilaciclib):首个也是唯一一种减少化疗诱导骨髓抑制发生率的骨髓保护疗法

阅读更多
12/22/20

2021年最值得买入的21只股票

阅读更多
12/18/20

城堡生物科学宣布结束普通股公开发行和充分行使承销商购买额外股份的选择权

阅读更多
12/15/20

Silicon Ranch Closes $225 Million Equity Raise with Existing Shareholders

阅读更多
12/9/20

2020年圣安东尼奥乳腺癌研讨会上，G1公司公布了三阴性乳腺癌转移性三阴性乳腺癌联合化疗的最终2期临床数据，显示总体生存期显著改善

阅读更多
11/2/20

Castle Biosciences Announces Commercial Launch of DecisionDx DiffDx-Melanoma

阅读更多
10/8/20

Castle Biosciences Announces Expanded Medicare Coverage for DecisionDx-Melanoma in Cutaneous Melanoma

阅读更多
10/6/20

PhaseBio Doses First Patients in Canada as Part of the REVERSE-IT Global Phase 3 Trial of Bentracimab

阅读更多
9/2/20

Castle Biosciences Announces Commercial Launch of DecisionDx-SCC

阅读更多
7/27/20

Mindera Corporation Announces Appointment of George W. Mahaffey担任总裁兼首席执行官

阅读更多
6/24/20

城堡生物科学宣布定价为74美元.2亿普通股公开发行

阅读更多
5/27/20

PhaseBio Launches Clinical Trial to Evaluate PB1046 as a Treatment for Hospitalized COVID-19 Patients

阅读更多
4/13/20

Orig3n Receives FDA Emergency Use Authorization (EUA) For Coronavirus 2019 Test

阅读更多
1/13/20

PhaseBio宣布获得新型口服醛固酮合成酶抑制剂，用于开发治疗难治高血压

阅读更多
1/10/20

PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® forPB2452

阅读更多
11/21/19

AN2 Therapeutics以1200万美元的A轮融资启动，并宣布与Brii Biosciences建立战略伙伴关系

阅读更多
11/19/19

Silicon Ranch signs on for 107-MW solar project for Facebook in Georgia

阅读更多
10/29/19

Castle Biosciences在美国皮肤外科学会(ASDS) 2019年年会上发布了其皮肤鳞癌预后测试的临床验证研究

阅读更多
10/15/19

PhaseBio宣布，首次有患者参与PB2452逆转替格瑞洛抗血小板活性的2b期临床试验

阅读更多
10/7/19

新发表的系统综述证实了强有力的证据，并概述了decision -Melanoma在皮肤黑色素瘤患者管理中的整合的适当使用标准

阅读更多
9/4/19

REGENXBIO宣布与Clearside Biomedical签订独家全球期权和许可协议，用于评估RGX-314的办公交付平台

阅读更多
8/14/19

PhaseBio Announces Receipt of Minutes of End-of-Phase 1 Meeting with the FDA and Alignment on a Single, Non-Randomized Phase 3 Trial to Support BLA Submission for PB2452

阅读更多
7/29/19

Castle Biosciences宣布首次公开发行(ipo)结束，并全面行使承销商购买额外股份的期权

阅读更多
6/26/19

Silicon Ranch推出再生能源™

阅读更多
6/18/19

G1 therapeutics宣布，三拉西布联合化疗2期临床试验的最新结果显示，转移性三阴性乳腺癌患者的总生存期有统计学意义的改善

阅读更多
6/17/19

PhaseBio宣布，PB2452逆转替格瑞洛在老年人和老年受试者抗血小板活性的2a期临床试验初步结果阳性

阅读更多
4/29/19

G1 Therapeutics Announces Positive Feedback from Trilaciclib End-of-Phase 2 Meeting with FDA; Expects to File NDA in 2020

阅读更多
4/8/19

PhaseBio Announces Closing of Public Offering of Common Stock

阅读更多
4/8/19

PhaseBio获得突破性治疗称号

阅读更多
3/19/19

应用LifeSciences & Systems Announces Closing of its $8 Million Series A Round of Equity Financing

阅读更多
3/17/19

Full Results from PhaseBio Phase I Clinical Trial Published in New England Journal of Medicine

阅读更多
3/6/19

独立展望出版物, Multicenter Study Reinforces Accuracy of DecisionDx-Melanoma Test Recurrence Risk Prediction

阅读更多
2/20/19

Clearside Receives Notification of FDA Acceptance of NDA Filing for XIPERE

阅读更多
2/7/19

最新发表的研究表明，decisiondx黑色素瘤预后测试准确识别头颈部黑色素瘤患者的风险

阅读更多
1/30/19

Castle Biosciences公布了一项前瞻性多中心研究，表明其DecisionDx-Melanoma测试可以告知前哨淋巴结活检决定

阅读更多
1/7/19

Castle Biosciences的decisiondx黑色素瘤测试在新发表的研究中，从传统上分期为低风险的黑色素瘤患者中识别出高风险黑色素瘤患者

阅读更多
12/6/18

Castle Biosciences Announces the Appointment of Genomic Health CFO G. Bradley Cole加入董事会

阅读更多
12/5/18

Silicon Ranch to Help Power Facebook Data Center in Georgia

阅读更多
10/18/18

Castle Biosciences Announces Medicare Coverage for the DecisionDx-Melanoma Test in Cutaneous Melanoma

阅读更多
8/27/18

PhaseBio Secures $34 Million in Series D Financing

阅读更多
7/30/18

Castle Biosciences发布的数据表明，DecisionDx-Melanoma Test改进了基于ajcc的Melanoma复发和转移风险预测

阅读更多
6/28/18

APPELLO完成10美元.5 MILLION SERIES A FINANCING LED BY DEERFIELD MANAGEMENT AND MOUNTAIN GROUP PARTNERS

阅读更多
5/31/18

Clearside Biomedical宣布CLS-TA与Eylea用于糖尿病黄斑水肿患者的2期临床试验阳性结果

阅读更多
5/23/18

歌公司. 获得Aspire健康

阅读更多
4/16/18

G1 Therapeutics宣布启动G1T38联合Tagrisso治疗egfr突变非小细胞肺癌1b/2期临床试验

阅读更多
3/28/18

Castle Biosciences Announces Inclusion of DecisionDx-UM Prognostic Test in New NCCN Guidelines for Uveal Melanoma

阅读更多
3/15/18

G1 Therapeutics宣布，Trilaciclib 2a期背线数据阳性，显示小细胞肺癌患者有良好的髓鞘保留益处

阅读更多
3/5/18

Clearside Biomedical宣布CLS-TA在非感染性葡萄膜炎相关黄斑水肿的关键3期临床试验中取得阳性结果

阅读更多
1/22/18

Shell Takes a Major Stake in US Solar Developer Silicon Ranch

阅读更多
1/22/18

Shell Acquires Interest in Silicon Ranch Corporation

阅读更多
1/4/18

AgTech Accelerator Launches First Investment in Novel Fungicide Company, Boragen Inc.该公司的A轮融资为1,000万美元

阅读更多
1/4/18

AgTech Accelerator Makes First 365app体育在线 Industry Investment in Skyline Vet Pharma with $5 Million Series A Financing

阅读更多
12/18/17

G1 Therapeutics Added to Nasdaq Biotechnology Index

阅读更多
9/18/17

G1 Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes

阅读更多
7/31/17

Myomo公司. 获得CE认证MyoPro®

阅读更多
7/13/17

G1 Therapeutics Appoints Sir Andrew Witty to Board of Directors

阅读更多
6/27/17

生物技术公司ORIG3N获得2000万美元

阅读更多
6/9/17

Myomo公司. 完成历史性的首次公开发行

阅读更多
5/30/17

G1公司将在2017年美国临床肿瘤学会年会上展示CDK4/6抑制剂Trilaciclib的临床数据

阅读更多
5/25/17

FUTURE Local Coverage Determination for MolDX: DecisionDxUM (Uveal Melanoma) (L37033)

阅读更多
5/16/17

G1 Therapeutics 宣布首次公开发行的定价

阅读更多
4/18/17

NeuroTronik宣布23美元.100万B轮优先股融资

阅读更多
3/29/17

G1 Therapeutics Announces Presentations at the 2017 American Association for Cancer Research Annual Meeting

阅读更多
1/10/17

G1 Therapeutics Initiates Three Drug Development Programs in Breast Cancer

阅读更多
12/5/16

G1药物评价三拉西布(G1T28)联合免疫检查点抑制剂治疗小细胞肺癌的疗效

阅读更多
11/2/16

AgTech Accelerator Corporation Announces the Addition of 365app体育在线 Pioneer Elanco to Blue-Chip Investor Syndicate; Completes $20 Million First Closing

阅读更多
9/21/16

NuSirt Biopharma and OWL Metabolomics Partner to Advance Treatment of NASH / Non-alcoholic Steatohepatitis

阅读更多
6/1/16

Clearside生物医学公司. 宣布首次公开发行的定价

阅读更多
5/11/16

G1 Therapeutics Secures $47 Million Series C Financing

阅读更多
4/27/16

Mississippi Power, Silicon Ranch break ground on new solar energy facility

阅读更多
4/27/16

Partners Group invests USD 100 million in Silicon Ranch Corporation, 我们的开发人员, owner and operator of solar power production facilities

阅读更多
4/26/16

Clearside生物医学公司. Announces Positive Preliminary Phase 2 Results in Patients with Macular Edema Associated with Retinal Vein Occlusion

阅读更多
4/15/16

TVA and Silicon Ranch Partner on Large-Scale Solar Farm at NSA Mid-South

阅读更多
2/1/16

A Local Startup Is Building the World’s Largest iPS Stem Cell Bank

阅读更多
1/26/16

Clinical Trial Results Show Synergy between NuSirt Technology and Metformin in Patients with Type 2 Diabetes

阅读更多
12/14/15

Clearside生物医学公司. 完成CLS-TA使用脉络膜上间隙(SCS™)药物管理治疗视网膜静脉阻塞的2期临床试验的登记

阅读更多
12/10/15

NuSirt Biopharma Receives FDA Fast Track Designation for Non-Alcoholic Fatty Liver Disease Treatment

阅读更多
12/3/15

Clearside生物医学公司. 完成2000万美元C轮融资

阅读更多
12/1/15

Green Power EMC and Silicon Ranch Dedicate 20 MW Georgia Solar Facility

阅读更多
1/15/15

Clearside生物医学公司. Initiates Phase 2 Clinical Trial For the Treatment of Macular Edema Associated With Non-Infectious Uveitis

阅读更多
7/7/14

NuSirt Biopharma Technology Presented at American Diabetes Association Scientific Sessions

阅读更多